PMID- 33474947
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220603
IS  - 2224-5839 (Electronic)
IS  - 2224-5820 (Linking)
VI  - 10
IP  - 2
DP  - 2021 Feb
TI  - The efficacy and safety of Osimertinib in advanced non-small cell lung cancer 
      patients with Thr790Met resistance mutations: a systematic review and 
      meta-analysis.
PG  - 1851-1860
LID - 10.21037/apm-20-1357 [doi]
AB  - BACKGROUND: Osimertinib, a third-generation epidermal growth factor 
      receptor-tyrosine kinase inhibitor (EGFR-TKI), has been approved by the U.S. Food 
      and Drug Administration in treating T790M mutationpositive advanced non-small 
      cell lung cancer (NSCLC). A systematic review and meta-analysis was conducted to 
      assess the efficacy and safety of osimertinib in treating advanced NSCLC patients 
      with acquired T790M mutation. METHODS: PubMed, EMBASE, Cochrane Library and Web 
      of Science were searched to obtain the eligible studies following the 
      "population, interventions, comparisons, outcomes, study design" (PICOS) 
      criteria. The pooled analysis of objective response rate (ORR), disease 
      controlled rate (DCR), progressionfree survival (PFS), overall survival (OS) and 
      adverse events (AEs) were performed using STATA12.0 and RevMan5.0. RESULTS: A 
      total of 1,050 patients were included in the meta-analysis. The combined 
      osimertinib ORR was 0.64 (95% CI, 0.60-0.69), the ORR of central nervous system 
      (CNS) was 0.54 (95% CI, 0.37-0.71), DCR was 0.89 (95% CI, 0.86-0.92), PFS at six 
      months (PFS-6m) rate was 0.69 (95% CI, 0.58-0.79), PFS at one year (PFS-1y) rate 
      was 0.33 (95% CI, 0.20-0.46), OS at one year (OS-1y) rate was 0.69 (95% CI, 
      0.55-0.84). The pooled incidence rate of the AEs of grade >/= III was 0.25 (95% CI, 
      0.09-0.40). The results from Begg's and Egger's tests presented no publication 
      bias in the included studies. CONCLUSIONS: Osimertinib demonstrated a superior 
      therapeutic benefit with high efficacy and low toxicity for T790M-positive 
      advanced NSCLC patients who were treated with early-generation EGFR-TKIs. 
      Meanwhile, osimertinib showed promising for the treatment of advanced patients 
      with CNS metastases.
FAU - Cui, Saijin
AU  - Cui S
AD  - Cancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 
      China.
FAU - Zhang, Yaling
AU  - Zhang Y
AD  - Cancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 
      China.
FAU - Liu, Lu
AU  - Liu L
AD  - Cancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 
      China.
FAU - Li, Yan
AU  - Li Y
AD  - Cancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 
      China.
FAU - Zhou, Rongmiao
AU  - Zhou R
AD  - Cancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 
      China.
FAU - Huang, Xi
AU  - Huang X
AD  - Cancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 
      China.
FAU - Cao, Shiru
AU  - Cao S
AD  - Cancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 
      China.
FAU - Huo, Xiangran
AU  - Huo X
AD  - Cancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 
      China.
FAU - Wang, Na
AU  - Wang N
AD  - Cancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 
      China. hbykdxwn@163.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20210114
PL  - China
TA  - Ann Palliat Med
JT  - Annals of palliative medicine
JID - 101585484
RN  - 0 (Acrylamides)
RN  - 0 (Aniline Compounds)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 3C06JJ0Z2O (osimertinib)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Acrylamides
MH  - Aniline Compounds
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics
MH  - ErbB Receptors/genetics
MH  - Humans
MH  - *Lung Neoplasms/drug therapy/genetics
MH  - Mutation
MH  - Protein Kinase Inhibitors/therapeutic use
OTO - NOTNLM
OT  - Osimertinib
OT  - T790M mutation
OT  - advanced non-small cell lung cancer (NSCLC)
OT  - central nervous system (CNS)
OT  - meta-analysis
EDAT- 2021/01/22 06:00
MHDA- 2021/05/15 06:00
CRDT- 2021/01/21 08:37
PHST- 2020/07/03 00:00 [received]
PHST- 2020/10/23 00:00 [accepted]
PHST- 2021/01/22 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2021/01/21 08:37 [entrez]
AID - apm-20-1357 [pii]
AID - 10.21037/apm-20-1357 [doi]
PST - ppublish
SO  - Ann Palliat Med. 2021 Feb;10(2):1851-1860. doi: 10.21037/apm-20-1357. Epub 2021 
      Jan 14.